Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges

Hepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world and its incidence is increasing in many countries. In recent years, with the deepening understanding of the immune and pathological mechanisms of HCC, immunotherapy based on the regulation of tumor immune microenvi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hao-Tian, Jiang, Meng-Jie, Deng, Zhu-Jian, Li, Le, Huang, Jian-Li, Liu, Zhen-Xiu, Li, Le-Qun, Zhong, Jian-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570111/
https://www.ncbi.nlm.nih.gov/pubmed/34745958
http://dx.doi.org/10.3389/fonc.2021.737497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570111/
https://www.ncbi.nlm.nih.gov/pubmed/34745958
http://dx.doi.org/10.3389/fonc.2021.737497

Ejemplares similares